EPHA2, a promising therapeutic target for hepatocellular carcinoma

被引：7

作者：

Wang, Hao

Qiu, Wei ^{[1
]}

机构：

[1] Loyola Univ Chicago, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA

来源：

MOLECULAR & CELLULAR ONCOLOGY | 2021年 / 8卷 / 03期

基金：

美国国家卫生研究院;

关键词：

EPHA2; HCC; AKT; STAT3; JAK1; INHIBITION; RECEPTOR; LIGAND;

D O I：

10.1080/23723556.2021.1910009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Identifying critical drivers of oncogenesis and tumor progression is essential for developing effective hepatocellular carcinoma (HCC) therapeutics. Our recent findings has demonstrated that targeting Ephrin Receptor A2 (EPHA2) suppresses HCC initiation and progression by dual inhibition of the Protein Kinase B (AKT) and Signal Transducer and Activator of Transcription 3 (STAT3) signaling.

引用

收藏

页数：3

相关论文

共 10 条

[1] Gene Expression Profiling of Muscle Stem Cells Identifies Novel Regulators of Postnatal Myogenesis [J].

Alonso-Martin, Sonia ;

Rochat, Anne ;

Mademtzoglou, Despoina ;

Morais, Jessica ;

de reynies, Aurelien ;

Aurade, Frederic ;

Chang, Ted Hung-Tse ;

Zammit, Peter S. ;

Relaix, Frederic .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2016, 4

[2] Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC [J].

Arnato, Katherine R. ;

Wang, Shan ;

Hastings, Andrew K. ;

Youngblood, Victoria M. ;

Santapuram, Pranav R. ;

Chen, Haiying ;

Cates, Justin M. ;

Colvin, Daniel C. ;

Ye, Fei ;

Brantley-Sieders, Dana M. ;

Cook, Rebecca S. ;

Tan, Li ;

Gray, Nathanael S. ;

Chen, Jin .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (05) :2037-2049

[3] Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors [J].

Choi, Yongmun ;

Syeda, Farisa ;

Walker, John R. ;

Finerty, Patrick J., Jr. ;

Cuerrier, Dominic ;

Wojciechowski, Amy ;

Liu, Qingsong ;

Dhe-Paganon, Sirano ;

Gray, Nathanael S. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) :4467-4470

[4] Mechanisms of ephrin-Eph signalling in development, physiology and disease [J].

Kania, Artur ;

Klein, Ruediger .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2016, 17 (04) :240-256

[5] EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt [J].

Miao, Hui ;

Li, Da-Qiang ;

Mukherjee, Amitava ;

Guo, Hong ;

Petty, Aaron ;

Cutter, Jennifer ;

Basilion, James P. ;

Sedor, John ;

Wu, Jiong ;

Danielpour, David ;

Sloan, Andrew E. ;

Cohen, Mark L. ;

Wang, Bingcheng .

CANCER CELL, 2009, 16 (01) :9-20

[6] AKT as a Therapeutic Target for Cancer [J].

Song, Mengqiu ;

Bode, Ann M. ;

Dong, Zigang ;

Lee, Mee-Hyun .

CANCER RESEARCH, 2019, 79 (06) :1019-1031

[7] Hepatocellular Carcinoma [J].

Villanueva, Augusto .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (15) :1450-1462

[8] Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling [J].

Wang, Hao ;

Hou, Wei ;

Perera, Aldeb ;

Bettler, Carlee ;

Beach, Jordan R. ;

Ding, Xianzhong ;

Li, Jun ;

Denning, Mitchell F. ;

Dhanarajan, Asha ;

Cotler, Scott J. ;

Joyce, Cara ;

Yin, Jun ;

Ahmed, Fowsiyo ;

Roberts, Lewis R. ;

Qiu, Wei .

CELL REPORTS, 2021, 34 (08)

[9] The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting [J].

Wykosky, Jill ;

Debinski, Waldemar .

MOLECULAR CANCER RESEARCH, 2008, 6 (12) :1795-1806

[10] Revisiting STAT3 signalling in cancer: new and unexpected biological functions [J].

Yu, Hua ;

Lee, Heehyoung ;

Herrmann, Andreas ;

Buettner, Ralf ;

Jove, Richard .

NATURE REVIEWS CANCER, 2014, 14 (11) :736-746